Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022
The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022, according to a new study from health care advisory firm Decision Resources.
Currently, the COPD market is dominated by Boehringer Ingelheim/Pfizer's long-acting muscarinic antagonist (LAMA) Spiriva (tiotropium) and GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) Advair/Seretide/Adoair (fluticasone and salmeterol). In 2012, total sales of these two market leaders constituted nearly two-thirds of COPD sales. However, following the launch of new agents, particularly those that offer advantages in dosing, their combined market share will diminish to less than 15% in 2022.
COPD drug sales to reach $14 billion in leading markets in 2022
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze